- About 75-80% of women have hot flashes during the menopause transition, and frequent symptoms last a median of roughly 7.4 years — for some, well over a decade.
- Hot flashes come from estrogen-related changes in the brain's temperature-control center (KNDy neurons in the hypothalamus), not from a true rise in core body temperature.
- Hormone therapy is the most effective option for women without contraindications, but several non-hormonal prescriptions work too, including SSRIs/SNRIs, gabapentin, and NK-receptor antagonists.
- Fezolinetant (Veozah) carries a 2024 FDA boxed warning for rare but serious liver injury and requires scheduled liver-function testing; elinzanetant (Lynkuet) was FDA-approved in October 2025.
- Everyday triggers — heat, hot drinks, spicy food, alcohol, caffeine, smoking, and stress — can set off individual episodes and are worth tracking.
- Which treatment fits depends on your personal risk profile; a clinician familiar with current menopause guidelines should help you choose.
——————————————————————————–
About three in four women going through the menopause transition experience hot flashes, and the median duration of frequent symptoms is roughly 7.4 years according to the landmark SWAN study. They are not just an inconvenience. Severe hot flashes are linked to sleep loss, lower productivity, and, in some studies, worse cardiovascular and bone outcomes. The good news is that today’s treatment options are far better than they were even a decade ago, with both hormonal and effective non-hormonal medications now available — including a newer class of drugs that targets the brain pathway behind hot flashes directly.
What Hot Flashes Are and How Common They Are
A hot flash is a sudden sensation of intense heat — usually starting in the chest, neck, or face — accompanied by flushing, sweating, and sometimes a chilled aftermath. Episodes typically last one to five minutes. When they occur during sleep and produce drenching sweat, they are called night sweats. Together they are termed vasomotor symptoms.
According to The Menopause Society (formerly the North American Menopause Society, or NAMS), roughly 75 to 80 percent of women experience hot flashes during the menopause transition. The SWAN study found Black women tend to experience them more frequently and for longer durations than other groups, and women of higher BMI often have more severe symptoms. About 10 to 20 percent of women find hot flashes severely debilitating. For wider context on the menopausal transition, see our medical conditions hub.
What Causes Hot Flashes
Hot flashes arise from a narrowed thermoregulatory zone in the hypothalamus. Estrogen withdrawal alters signaling in the kisspeptin/neurokinin B/dynorphin (KNDy) neurons of the hypothalamus, which help regulate body temperature. A 2018 review in Endocrinology describes how this disrupted signaling triggers inappropriate heat-dissipation responses — vasodilation and sweating — even when core body temperature has not actually risen.
This neurobiological understanding is why neurokinin-receptor antagonists, which act on the KNDy pathway, have become an important non-hormonal option. Fezolinetant, a neurokinin 3 (NK3) receptor antagonist, became the first pathway-targeted non-hormonal treatment when the FDA approved Veozah in May 2023. In October 2025 the FDA approved a second drug in this space, elinzanetant (Lynkuet), the first dual NK1/NK3 receptor antagonist for menopausal hot flashes.
Triggers That Can Make Hot Flashes Worse
While the underlying cause is neuroendocrine, day-to-day triggers can precipitate individual episodes. Common ones include warm rooms, hot drinks, spicy foods, alcohol (especially red wine), caffeine, smoking, stress, and tight or synthetic clothing. Mayo Clinic notes that identifying personal triggers is one of the simplest first steps, though for many women, lifestyle modification alone is not enough.
Hot flashes can also occur outside of perimenopause and menopause. Tamoxifen, aromatase inhibitors, GnRH agonists, surgical menopause, opioid withdrawal, and some medications can cause vasomotor symptoms. Less commonly, thyroid dysfunction, carcinoid syndrome, or pheochromocytoma cause flushing episodes that may be mistaken for hot flashes.
How Hot Flashes Are Evaluated
For women in the menopause transition, no testing is usually needed to diagnose hot flashes — the clinical history is generally sufficient. Evaluation focuses on whether something else might be contributing and what treatment is appropriate. A clinician will typically review medications, ask about sleep, mood, cardiovascular history, breast cancer history, and clotting-risk factors.
Lab testing may include TSH if thyroid disease is suspected, since hyperthyroidism can mimic flushing and heat intolerance. According to ACOG, FSH testing is not routinely useful for diagnosis in symptomatic women over 45. When hot flashes occur in younger women, a broader workup for primary ovarian insufficiency, medications, and rare causes may be appropriate.
Treatment Options
Hormone therapy remains the most effective treatment, reducing hot-flash frequency and severity substantially — by roughly 75 percent in clinical trials. The Menopause Society’s 2022 Hormone Therapy Position Statement supports systemic menopausal hormone therapy as first-line for moderate-to-severe vasomotor symptoms in healthy women under 60 or within 10 years of menopause, when contraindications are absent. Whether hormone therapy is appropriate for you is an individualized decision your clinician makes with you.
For women who cannot or prefer not to use hormones, several non-hormonal prescriptions have evidence. Low-dose paroxetine 7.5 mg (Brisdelle) is the only FDA-approved SSRI product specifically for hot flashes, but other SSRIs and SNRIs — venlafaxine, escitalopram, citalopram, and desvenlafaxine — also reduce hot flashes by roughly 25 to 65 percent in trials. Gabapentin (especially for night-time symptoms) and oxybutynin are additional options. Among the pathway-targeted drugs, fezolinetant 45 mg daily reduced moderate-to-severe hot flashes by about 60 percent versus about 45 percent for placebo in the SKYLIGHT trials, and elinzanetant reduced frequency by more than 70 percent versus roughly 47 percent for placebo at 12 weeks in the OASIS program. All of these are prescription decisions weighed against your medical history.
Important safety update on NK-receptor drugs: In December 2024 the FDA added a boxed warning to fezolinetant (Veozah) for rare but serious liver injury and updated the recommended monitoring, which now includes liver-function testing before starting, monthly for the first two months, and again at months 3, 6, and 9 of treatment. Patients should report symptoms such as fatigue, nausea, itching, yellowing of the eyes or skin, pale stools, or dark urine promptly. Elinzanetant (Lynkuet), approved in October 2025, has its own labeling and monitoring considerations. Your clinician decides whether either drug is appropriate and how you should be monitored.
Non-pharmacologic approaches with reasonable evidence include cognitive behavioral therapy, clinical hypnosis, and weight loss for women with overweight or obesity. The Menopause Society’s 2023 Nonhormone Therapy Position Statement specifically notes good evidence for CBT and hypnosis. Common practices like soy isoflavones, black cohosh, and yoga have mixed or modest evidence.
When to See a Doctor
Many women manage mild hot flashes with simple lifestyle adjustments and never need a clinician’s help. But when symptoms disrupt sleep most nights, affect work performance, or persist for years without improvement, a conversation about prescription options is reasonable. Women under age 45 with new vasomotor symptoms should be evaluated for early menopause, medication effects, or other causes.
Hot flashes accompanied by other concerning features deserve prompt assessment. Episodes with diarrhea, wheezing, or facial flushing that follows specific foods may suggest carcinoid. Drenching night sweats with weight loss or fevers can signal infection or malignancy.
When to seek emergency care: Call 911 or go to the nearest emergency room if a hot-flash episode is accompanied by chest pain, severe shortness of breath, fainting, sudden severe headache, one-sided weakness or speech changes, or any features suggesting a heart attack, stroke, or anaphylaxis.
Frequently Asked Questions
How long do hot flashes last?
The SWAN study found a median duration of frequent vasomotor symptoms of about 7.4 years from onset, with roughly a third of women having symptoms for more than 10 years. Women whose hot flashes start in early perimenopause tend to have the longest courses.
Can men get hot flashes?
Yes. Men on androgen-deprivation therapy for prostate cancer commonly develop hot flashes, and a similar neurobiological mechanism applies. Treatment options overlap with those used for women, including SSRIs and gabapentin.
Do natural remedies actually work?
Evidence is mixed. Black cohosh, soy isoflavones, and red clover have shown modest benefit in some trials and no benefit in others. The Menopause Society does not recommend them as first-line therapy. Cognitive behavioral therapy and clinical hypnosis have stronger evidence than most herbal options.
Is fezolinetant safer than hormone therapy?
It is not simply “safer” — it is different. Fezolinetant avoids the breast and clotting risks associated with hormones, but because of a rare risk of serious liver injury it now carries a boxed warning and requires scheduled liver-function testing. The Menopause Society considers NK-receptor antagonists a reasonable option for women who cannot or do not wish to use hormone therapy, but the choice, and the required monitoring, are decisions for your clinician. Cost and insurance coverage are also practical considerations.
The Bottom Line
Hot flashes are common, often long-lasting, and treatable. Hormone therapy works best for women without contraindications, but several effective non-hormonal options exist — from SSRIs/SNRIs and gabapentin to the newer NK-receptor antagonists — for those who cannot or prefer not to use hormones. Because each option carries its own benefits, risks, and monitoring requirements, the right choice depends on your individual profile. If symptoms are disrupting sleep, work, or daily life, a clinician familiar with current menopause guidelines can help match treatment to your risks and preferences. Tracking trigger patterns, episodes per day, and night-time symptoms before your visit makes the conversation more productive.
Medical disclaimer: This article is for general education only and is not medical advice. Hot flashes and menopause symptoms have many possible causes and treatments, and the best option depends on your personal health history and risks. Prescription treatments discussed here — including hormone therapy, SSRIs/SNRIs, gabapentin, and NK-receptor antagonists such as fezolinetant and elinzanetant — must be prescribed and monitored by a licensed clinician. Do not start or stop any medication on your own. If you have chest pain, severe shortness of breath, fainting, or stroke-like symptoms, call 911.
Sources
- The Menopause Society (formerly NAMS) — menopause symptom primer; 2022 Hormone Therapy and 2023 Nonhormone Therapy Position Statements.
- SWAN study — duration of vasomotor symptoms (median ~7.4 years).
- Mayo Clinic — hot flashes: symptoms, causes, and triggers.
- ACOG — Management of Menopausal Symptoms (Practice Bulletin).
- FDA — approval of Veozah (fezolinetant, May 2023); December 2024 boxed warning and liver-monitoring update; approval of Lynkuet (elinzanetant, October 24, 2025).
- The Lancet — SKYLIGHT trials (fezolinetant) and OASIS program (elinzanetant).